🔗 Share this article

While the US proceeds with sweeping adjustments to its immunization recommendations, a particular individual appears in a surprising turn: Tracy Beth Høeg, a US-based physician and epidemiologist who rose to prominence by casting doubt on COVID-19 vaccinations throughout the pandemic and has focused upon potential fatalities after COVID-19 vaccination in her recent tenure at the US Food and Drug Administration (FDA).

Planned Shifts to Childhood Immunization Program

Agency leaders planned to announce major revisions to the childhood vaccination calendar earlier this month, bringing the US with the Danish national calendar, sources say – a significant shift that would put the US out of alignment with much of the global community with little proof for improved outcomes. The planned update has been postponed until the next year.

In place of Vinay Prasad, Dr. Høeg is listed to speak at the event. She was just designated temporary leader of the FDA’s CDER, the fifth appointee to run the office this year.

A New Direction at the Agency

This interim role could signify a tighter collaboration between the drug and vaccine branches as Høeg and Dr. Prasad consolidate power at the agency – and it suggests a greater focus upon rolling back already-approved immunizations at the FDA.

The new acting director has frequently advocated for discontinuing some pediatric immunization guidelines in the US in order to be more similar to Denmark, a country with comprehensive healthcare and a population about the size of Wisconsin’s.

So far public appearances, she has kept her attention on immunizations – typically the domain of Prasad, director of the FDA’s vaccine center – rather than medication approval.

Questions Over Expertise

Høeg has little discernible background in drug development, oversight or administrative roles, which has been typical for former heads of the biologics center. She has been employed at the FDA as a top consultant to the commissioner and CBER since spring.

“She appears not to have the requisite experience” for leading the drug-regulation department, remarked Dr. Jonathan Howard. “She has not conducted a scientific study. She has no expertise in leading a major agency. She lacks background in drug approvals.”

Previous commissioners of CBER would “grasp legal statutes and the science of medication creation”, commented a former acting FDA commissioner. “Clearly, she has not acquired the type of experience that previous people who led the center have had.”

This division has an vast portfolio at the agency, the former commissioner stated.

“The public just zeroes in on the novel medication approvals, but the generic program approves numerous off-brand pharmaceuticals. There is also a biosimilars program, over-the-counter program and so forth, and every single one need to be managed,” Woodcock explained. “The area you overlook, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a significant leadership aspect to the position, which supervises in excess of 5,000 employees. “It is a huge management job, if you perform it correctly,” the former official concluded.

Response and Contentious Programs

Regarding concerns about Dr. Høeg's qualifications and whether this selection represents more teamwork among agency officials on immunizations, a representative stated that the “questions stem from incorrect assumptions”.

“Her experience is consistent with the duties of her role,” the official stated, citing the time Dr. Høeg spent advising the FDA commissioner on “medication safety and approval science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Høeg inherits the commissioner’s new priority voucher program, a disputed one-day drug-approval program that apparently troubled her preceding directors. “By what process are these medications being selected for this fast-track system? Who makes the choices?” Howard asked. “There’s a lot of confidentiality occurring at the agency right now.”

In general, he stated, “the agency seems to be moving towards laxer oversight of pharmaceuticals, with the exception of vaccines.”

Established History on Vaccines

Concerning immunizations, Høeg has a clearer, if troubling, track record, critics said. She published a analysis using unconfirmed public submissions to assess the frequency of myocarditis following Covid immunization. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who reportedly have modified findings to imply Covid vaccines are more dangerous than they are.

Included in her “policy goals” for the current administration featured changing rules for novel immunizations and halting “unnecessary” immunizations, she remarked post-election on a online show. At the agency, Dr. Høeg has allegedly floated the idea of excluding young men from getting COVID-19 vaccines.

“She is an all-around true believer who starts off with her conclusions and tailors the evidence to accommodate the evidence in a very misleading, dishonest fashion,” Howard stated.

Consolidating Power and a “Push for Payback”

Dr. Høeg aligned with other skeptics, {like|